Endo Int'l (ENDP) Tops Q2 EPS by 12c, Affirms Guidance

Endo Reports Second Quarter 2016 Financial Results

August 8, 2016 4:29 PM EDT

DUBLIN, Aug. 8, 2016 /PRNewswire/ --

Second quarter 2016 reported revenues of $921 million and diluted GAAP earnings per share (EPS) from continuing operations of $1.75 Second quarter 2016 adjusted diluted EPS of $0.86 Company affirms full year 2016 revenue and adjusted diluted EPS financial guidance Company expands management capabilities, appointing Joseph J. Ciaffoni to President, U.S. Branded Pharmaceuticals

Endo International plc (NASDAQ: ENDP) (TSX: ENL) today reported second quarter 2016 financial results, including:

Revenues of $921... More

Endo Announces Appointment of Joseph J. Ciaffoni as President, U.S. Branded Pharmaceuticals

August 8, 2016 4:06 PM EDT

DUBLIN, Aug. 8, 2016 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today the appointment of Joseph J. Ciaffoni as President, U.S. Branded Pharmaceuticals, effective August 15, 2016.  

"We are excited to announce the addition of Joe to the Endo executive team. His industry experience is extensive and includes building commercial businesses, leading multi-function organizations and achieving stellar results across primary care, specialty and rare disease markets. His proven track record of success across nearly 20 product launches and the commercialization of more than 70... More